<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Revised USMCA Pact Reveals New Pharma Provisions
Image Overlay - Revised USMCA Pact Reveals New Pharma Provisions

Revised USMCA Pact Reveals New Pharma Provisions

Revised USMCA Pact Reveals New Pharma Provisions

Although it has yet to be ratified by Congress, there appears to be a clear path forward to approval of the U.S.-Mexico-Canada Agreement (USMCA) for trade among the three North American countries. Among the updates in the revised agreement are a few that affect the pharma industry: the removal of a 10-year exculsivity provision for biologic drugs, opening the way for biosimilar competition, and provisions to encourage competition among drug companies to reduce prices. This is a mixed bag for pharma companies, but it will open the way to more clinical trials for generic/biosimilar products for existing biologic drugs, a boon to patients and to companies invested in biosimilar development. With our global network and extensive temperature-controlled packaging and premium courier capabilities, Yourway is positioned to support companies investigating biosimilars in clinical trials.

Back to Index
Media

Upcoming Events

Precision in Pharma Supply Chain & Logistics Summit (Munich)

April 15-16, 2024
Science Congress Center Munich

GCSG 2024 US Conference

April 21-24, 2024
Naples, Florida

Media

Articles

The At-home Trial Experience: Leveraging value-chain to reach and retain patients

Open chat
Come chat with us!
Hello! How can I help you?